

SUPPLEMENTARY FIGURE 6: Cox proportional-hazard analysis for the low-dose CM treatment effect on Overall Survival (OS) **(A)**, Distant Recurrence-Free Interval (DRFI) **(B)** and Breast Cancer-Free Interval (BCFI) **(C)**, respectively, according to the Bareche molecular subtypes. The p inter represents a Wald test that evaluates the effect of the treatment by variable interaction. CM group represents patients with metronomic treatment whereas no-CM group did not receive it. Blue color represents the CM cohort and yellow represent no-CM cohort. BL: Basal-like; IM: Immunomodulatory; LAR: Luminal Androgen-receptor; M: Mesenchymal; MSL: Mesenchymal Stem-like.

